Proteolix, Inc.

Proteolix, Inc., is a private biotechnology company with its headquarters in South San Francisco, California. Proteolix focuses primarily on the proteasome as a therapeutic target. Its lead product candidate, carfilzomib (PR-171), is a tetrapeptide epoxyketone currently in both Phase 1 and Phase 2 clinical trials in the United States and Canada. Carfilzomib's current route of administration is intravenous, and the company is exploring its potential utility in multiple myeloma, Non-Hodgkin lymphoma (NHL) and other cancers.

Proteolix's corporate website is [http://proteolix.com] .